🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#EuroPCR 2024 is fast approaching and to prepare for the Course, this year we have prepared the #EIJchallenge, which will put your knowledge of the journal and cardiovascular medicine to the test. It will unfold in 2 parts: an online challenge on social media (Level 1) and then

Parenteral administration of antiplatelet therapy can be preferred in patients presenting with ACS due to several reasons, including pharmacokinetic considerations, decreased cardiac output, gastrointestinal disorders, concomitant medications or a state of unconsciousness

Selatogrel is a P2Y12 inhibitor for subcutaneous self-administration in ACS. Phase 2 studies showed a strong inhibition of platelet reactivity, while the phase 3 randomized SOS-AMI Trial is investigating the efficacy and safety of selatogrel in patients developing a repeat MI.

Zalunfiban is a novel subcutaneous GPI that causing lower rates of bleeding and thrombocytopenia. It showed a high-grade platelet inhibition in a phase 2 investigation and is currently under evaluation in STEMI patients enrolled in the phase 3 randomized CELEBRATE Trial

Excellent educational paper by Davide Capodanno et al. shedding 💡into periprocedural #AMI published #EHJACVC Are there any unmet needs in current definition? Is an update 🚆 at 5th Universal #AMI definition? Check it out 👇 doi.org/10.1093/ehjacc… European Society of Cardiology Maria Bergami, MD, PhD 👇

Trial after trial, and with safer stent platforms, dual antiplatelet therapy (DAPT) durations are decreasing. But are we ready to eliminate DAPT entirely? We wrote this viewpoint to summarize the evolutionary journey of trials on aspirin-free strategies after percutaneous

This is a study inspired from and dedicated to Sanjay Kaul, where we investigated the effect of using absolute rather than relative noninferiority margins in cardiovascular randomized trials. Recalculating noninferiority margins based on actual event rates, rather than expected

Sodium-glucose cotransporter-2 are currently indicated for several medical conditions beyond diabetes mellitus, with ongoing drug repurposing further expanding their indications. rdcu.be/dN9We

How do you manage in-stent restenosis? Comparable clinical outcomes for sirolimus-coated balloon and thin-strut DES. A registry comparison @wwojakowski Fabrizio D'Ascenzo Wojciech Wańha Antonio Greco Rafał Wolny Lukasz Kuzma Sylwia Iwańczyk #cardiotwitter ahajrnls.org/4cMVVIJ

How many times have we seen this flow chart on the duration of DAPT change over the years? Let’s summarize the situation regarding class I recommendations (“must be done”) as reported in the new 2024 guidelines on chronic coronary syndromes: - High bleeding risk patient: DAPT

📣 Pusblished in EuroIntervention our work on ISR treatment 🌐 1367 ISR pts from the ULTRA and DEB-DRAGON Registries 🎈ULTRAthin DES ⬇️ DOCE, TLR and TVR compared to both DEB and Thin-DES 📍Risk reduction especially in diffuse ISR, while in focal ISR no difference with DEB

Properly selecting #DES for #PCI is of crucial importance, particularly in the context of a short DAPT duration and/or in patients at #HBR. Here is a summary of available evidence and approval status. shorturl.at/1B0Id Marco Spagnolo Davide Capodanno

Anti-inflammatory Strategies After Myocardial Infarction: the #TITIAN study 🔥 Now published in #EHJPharmacotherapy 💊 👉 academic.oup.com/ehjcvp/advance… EHJ-CVP Editor-in-Chief 👨‍💼 European Society of Cardiology Journals 📚 European Society of Cardiology 💟 Davide Capodanno Claudio Laudani Antonio Greco Giovanni Occhipinti Marco Spagnolo #CardioEd

🚨 Changes in Factor XI Activity Levels in Patients with #STEMI Undergoing Primary PCI 🫀 📌 Marco Spagnolo and colleagues found ⬆️ FXIa levels at discharge in STEMI patients undergoing #PCI Read on TH 👉📖 thieme-connect.com/products/ejour… #Cardiology #Thrombosis

Lipoprotein (a) contributes to the development and progression of atherosclerotic cardiovascular disease, but awareness on its role and Lp(a) testing remain limited. Lp(a)-lowering drugs are a potential breakthrough to improve cardiovascular outcomes. shorturl.at/IyjFQ

A review of the evidence on the association of lipoprotein (a) and cardiovascular disease, focusing on emerging targeted therapies. Antonio Greco, Davide Capodanno Marco Spagnolo Claudio Laudani Denise Faro Nicola Ammirabile ahajournals.org/doi/full/10.11…

We performed a systematic review and network meta-analysis to assess the completeness, optimal timing, and clinical guidance of percutaneous coronary intervention in myocardial infarction with multivessel disease. Immediate complete revascularization reduces the risk of

From STEMI pretreatment to long-term strategies, guidelines on antithrombotic therapy after PCI are clear, but real-world choices are still full of uncertainty. Here is a visual summary of key recommendations. PCRonline 🫀